The pharma firm reported a US$1.65 billion loss in Q4 2025, driven by a major write-down and falling Covid-19 product sales.

Pfizer has fallen behind the pack when it comes to GLP-1 drugs, but the company is still fighting.

Pfizer has spent billions of dollars on acquisitions in the past few decades. Its biggest deals include Warner-Lambert, ...

The healthcare giant has had trouble winning over investors in the past year despite an incredibly low valuation.

The U.S. stock market is drifting through mixed trading, while gold and silver bounce back from their latest sell-off.

On January 21, 2026, the Ministry of Health of the Republic of Azerbaijan hosted a meeting with a regional delegation from ...

The Brooklyn Daily Eagle editorial staff highlights images from around the world, photos courtesy of the Associated Press.

The data on Pfizer's GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs ...

Pfizer Inc. Buy: market overreacts to Q4 loss and 2026 guidance; oncology-led growth, 102-candidate pipeline, and dividend ...

Is Pfizer stock a buy at under 9x earnings? Yes. It is.

Pfizer on Tuesday hailed a study of a weight-loss-drug candidate while forecasting a profit decline due to the impact of the ...

Pfizer (PFE) stock dips as the company projects a revenue decline for 2026 amid a nearly $1.5B impact attributed to patent ...